Applied Data Analytics Annual Survey of the Global Syringe and Injectors Marketplace Finds Specialty Devices Continuing to Make Gains
Amherst, NH -- (SBWIRE) -- 09/13/2013 -- As the number of new drugs developed and approved for injection increases, the injectable device infrastructure continues to make strides in addressing the evolving needs of drug developers. Essentially a niche market just a few years ago, the number of syringes and injectors that are designed to be marketed as prefilled products has increased dramatically, and is set to become the most prevalent injectable product category by 2017.
While innovation and market share gains are occurring across all prefillable device categories, some segments are attracting escalating levels of interest, in the process demonstrating the potential to alter the injectable drug landscape.
In the area of prefillable plastic syringes, six separate device suppliers now offer a total of eight distinct branded devices, an increase from only three five years ago. While non-glass prefillable syringes have been largely confined to the area of emergency medicine, a number of drug developers are actively examining the benefits of this technology.
Autoinjectors have clearly become the most active injectable device segment, as drug marketers continue to search for ways to differentiate their products in the eyes of consumers as well as caregivers, and to address user safety concerns. The appearance of the disposable autoinjector three years ago has led to a period of rapid growth and diversification, as these devices, once considered strictly an after-market accessory for diabetes patients, now compete on an equal footing with pen injectors for market share.
As often happens in industry when a new technology gains traction, the rise of the prefilled injection device has spawned a budding industry of supply chain participants actively working with device suppliers on both an OEM and post-manufacturing basis. The number of ‘Fill & Finish’ facilities worldwide is growing at thirty percent annually, as CMOs strive to establish relationships with drug developers as well as device suppliers.
These conclusions are taken from a recent survey conducted by Applied Data Analytics. The survey’s findings can be found in a new and comprehensive report: Global Syringe & Injector Analysis and Assessment. This global report contains highly detailed data and knowledge on device designs, combination products, supplier relationships, market share information and data forecasts.
For more information, please visit:
Global Syringe and Injector Annual Assessment and Analysis
About Applied Data Analytics
Applied Data Analytics assists life science management decision makers by providing analysis services and products that can reveal key relationships, patterns and trends affecting their businesses. These information tools encourage opportunity and risk discovery by promoting comprehensive, timely, and insightful analysis, allowing managers to make informed tactical and strategic decisions.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)